• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Capstone Holding Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    1/9/26 5:15:24 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CAPS alert in real time by email
    false 0000887151 0000887151 2026-01-07 2026-01-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): January 7, 2026

     

    CAPSTONE HOLDING CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-33560   86-0585310
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    5141 W. 122nd Street

    Alsip, IL 60803

    (Address of principal executive offices)

     

    Registrant’s telephone number, including area code: (708) 371-0660

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0005 per share   CAPS   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    On January 7, 2026, Capstone Holding Corp. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on The Nasdaq Capital Market under the symbol “CAPS” at this time.

     

    In accordance with Nasdaq Listing Rule 5810(c)(3)(a), the Company has been given 180 calendar days, or until July 6, 2026, to regain compliance with the Minimum Bid Price Requirement. If at any time before July 6, 2026, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance.

     

    If the Company does not regain compliance with the Minimum Bid Price Requirement by July 6, 2026, the Company may be eligible for an additional 180 calendar day period to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the Minimum Bid Price Requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the deficiency during the second compliance period. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company’s securities are subject to delisting.

     

    The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing Rules.

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K contains forward-looking statements. Statements that are not historical facts, including statements about beliefs or expectations, are forward-looking statements. These statements are based on plans, estimates, expectations and projections at the time the statements are made, and readers should not place undue reliance on them. In some cases, readers can identify forward-looking statements by the use of forward-looking terms such as “may,” “will,” “should,” “expect,” “opportunity,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other comparable terms. Forward-looking statements involve inherent risks and uncertainties and readers are cautioned that a number of important factors could cause actual results to differ materially from those contained in any such forward-looking statements. Factors that could cause actual results to differ materially from those described in this press release including those risks that may be included in the periodic reports and other filings that the Company files from time to time with the U.S. Securities and Exchange Commission. Forward-looking statements included in this Current Report on Form 8-K speak only as of the date each statement is made. Neither the Company nor any person undertakes any obligation to update any of these statements in light of new information or future events, except to the extent required by applicable law.

     

    1 

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: January 9, 2026 Capstone Holding Corp.
         
      By: /s/ Matthew E. Lipman
      Name: Matthew E. Lipman
      Title: Chief Executive Officer

     

     

     

    2

     

    Get the next $CAPS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAPS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CAPS
    SEC Filings

    View All

    Amendment: Capstone Holding Corp. filed SEC Form 8-K: Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

    8-K/A - Capstone Holding Corp. (0000887151) (Filer)

    2/17/26 5:25:27 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14C filed by Capstone Holding Corp.

    DEF 14C - Capstone Holding Corp. (0000887151) (Filer)

    2/12/26 4:29:10 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14C filed by Capstone Holding Corp.

    PRE 14C - Capstone Holding Corp. (0000887151) (Filer)

    1/30/26 5:28:57 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Schultz Edward Christopher

    3 - Capstone Holding Corp. (0000887151) (Issuer)

    4/22/25 3:55:58 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Lipman Matthew E. claimed ownership of 2,650,436 shares (SEC Form 3)

    3 - Capstone Holding Corp. (0000887151) (Issuer)

    4/22/25 3:53:49 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Holliman John M Iii claimed ownership of 1,095 shares (SEC Form 3)

    3 - Capstone Holding Corp. (0000887151) (Issuer)

    4/14/25 7:04:52 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care